Analysis of the interactions between HIV-1 and the cellular prion protein in a human cell line

Journal of Molecular Biology

Volumn 337, Issue 4, 2004, Pages 1035-1051

  Leblanc, Pascal ^a,c   Baas, Dominique ^b,c   Darlix, Jean Luc ^a,c  

^a UNIVERSITÉ DE LYON   (France)

^b INSTITUT DE BIOLOGIE ET CHIMIE DES PROTÉINES   (France)

^c University Lyon i   (France)

Author keywords

GPI, glycosylphosphatidylinositol; HIV 1; HIV 1, human immunodeficiency virus type 1; LRP, the laminin receptor protein; PrPc; PrPc, cellular prion protein; STI 1, the stress inducible protein 1; Viral production

Indexed keywords

PRION PROTEIN; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RNA SPLICING; RNA SYNTHESIS; VIRUS INFECTION; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MAMMALIA;

EID: 1642363337     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.02.007     Document Type: Article

References (69)

1. Ford M.L., Burton L.J., Morris R.J., Hall S.M. Selective expression of prion protein in peripheral tissues of the adult mouse. Neuroscience. 113:2002;177-192.
2. Ivanova L., Barmada S., Kummer T., Harris D.A. Mutant prion proteins are partially retained in the endoplasmic reticulum. J. Biol. Chem. 276:2001;42409-42421.
3. Lee K.S., Magalhaes A.C., Zanata S.M., Brentani R.R., Martins V.R., Prado M.A. Internalization of mammalian fluorescent cellular prion protein and N-terminal deletion mutants in living cells. J. Neurochem. 79:2001;79-87.
4. Magalhaes A.C., Silva J.A., Lee K.S., Martins V.R., Prado V.F., Ferguson S.S., et al. Endocytic intermediates involved with the intracellular trafficking of a fluorescent cellular prion protein. J. Biol. Chem. 277:2002;33311-33318.
5. Gu Y., Verghese S., Mishra R.S., Xu X., Shi Y., Singh N. Mutant prion protein-mediated aggregation of normal prion protein in the endoplasmic reticulum: implications for prion propagation and neurotoxicity. J. Neurochem. 84:2003;10-22.
6. Naslavsky N., Stein R., Yanai A., Friedlander G., Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J. Biol. Chem. 272:1997;6324-6331.
7. Vey M., Pilkuhn S., Wille H., Nixon R., DeArmond S.J., Smart E.J., et al. Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc. Natl Acad. Sci. USA. 93:1996;14945-14949.
8. Harris D.A. Cellular biology of prion diseases. Clin. Microbiol. Rev. 12:1999;429-444.
9. Mouillet-Richard S., Ermonval M., Chebassier C., Laplanche J.L., Lehmann S., Launay J.M., Kellermann O. Signal transduction through prion protein. Science. 289:2000;1925-1928.
10. Mange A., Nishida N., Milhavet O., McMahon H.E., Casanova D., Lehmann S. Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J. Virol. 74:2000;3135-3140.
11. Chiarini L.B., Freitas A.R., Zanata S.M., Brentani R.R., Martins V.R., Linden R. Cellular prion protein transduces neuroprotective signals. EMBO J. 21:2002;3317-3326.
12. Brown K.L., Stewart K., Ritchie D.L., Mabbott N.A., Williams A., Fraser H., et al. Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells. Nature Med. 5:1999;1308-1312.
13. Milhavet O., McMahon H.E., Rachidi W., Nishida N., Katamine S., Mange A., et al. Prion infection impairs the cellular response to oxidative stress. Proc. Natl Acad. Sci. USA. 97:2000;13937-13942.
14. Roucou X., Gains M., LeBlanc A.C. Neuroprotective functions of prion protein. J. Neurosci. Res. 75:2004;153-161.
15. Lee K.S., Linden R., Prado M.A., Brentani R.R., Martins V.R. Towards cellular receptors for prions. Rev. Med. Virol. 13:2003;399-408.
16. Ma J., Lindquist S. Wild-type PrP and a mutant associated with prion disease are subject to retrograde transport and proteasome degradation. Proc. Natl Acad. Sci. USA. 98:2001;14955-14960.
17. Ma J., Lindquist S. Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science. 298:2002;1785-1788.
18. Cohen E., Taraboulos A. Scrapie-like prion protein accumulates in aggresomes of cyclosporin A-treated cells. EMBO J. 22:2003;404-417.
19. Nandi P.K., Leclerc E. Polymerization of murine recombinant prion protein in nucleic acid solution. Arch. Virol. 144:1999;1751-1763.
20. Cordeiro Y., Machado F., Juliano L., Juliano M.A., Brentani R.R., Foguel D., Silva J.L. DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation. J. Biol. Chem. 276:2001;49400-49409.
21. Gabus C., Auxilien S., Pechoux C., Dormont D., Swietnicki W., Morillas M., et al. The prion protein has DNA strand transfer properties similar to retroviral nucleocapsid protein. J. Mol. Biol. 307:2001;1011-1021.
22. Gabus C., Derrington E., Leblanc P., Chnaiderman J., Dormont D., Swietnicki W., et al. The prion protein has RNA binding and chaperoning properties characteristic of nucleocapsid protein NCp7 of HIV-1. J. Biol. Chem. 276:2001;19301-19309.
23. Adler V., Zeiler B., Kryukov V., Kascsak R., Rubenstein R., Grossman A. Small, highly structured RNAs participate in the conversion of human recombinant PrPsen to PrPres in vitro. J. Mol. Biol. 332:2003;47-57.
24. Deleault N.R., Lucassen R.W., Supattapone S. RNA molecules stimulate prion protein conversion. Nature. 425:2003;717-720.
25. Muller W.E., Pfeifer K., Forrest J., Ryti k P.G., Eremin V.F., Popov S.A., Schroder H.C. Accumulation of transcripts coding for prion protein in human astrocytes during infection with human immunodeficiency virus. Biochim. Biophys. Acta. 1139:1992;32-40.
26. Neumann M., Felber B.K., Kleinschmidt A., Froese B., Erfle V., Pavlakis G.N., Brack-Werner R. Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function. J. Virol. 69:1995;2159-2167.
27. Ludwig E., Ceccherini-Silberstein F., Van Emple J., Erfle V., Neumann M., Brack-Werner R. Diminished Rev-mediated stimulation of human immunodeficiency virus type 1 protein synthesis is hallmark of human astrocytes. J. Virol. 73:1999;8279-8289.
28. Gorry P.R., Howard J.L., Churchill M.J., Anderson J.L., Cunningham A., Adrian D., et al. Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. J. Virol. 73:1999;352-361.
29. Nakamura Y., Sakudo A., Saeki K., Kaneko T., Matsumoto Y., Toniolo A. Transfection of prion protein gene suppresses coxsackievirus B3 replication in prion protein gene-deficient cells. J. Gen. Virol. 84:2003;3495-3502.
30. Lehmann S., Harris D.A. Blockade of glycosylation promotes acquisition of scrapie-like properties by the prion protein in cultured cells. J. Biol. Chem. 272:1997;21479-21487.
31. Lehmann S., Milhavet O., Mange A. Trafficking of the cellular isoform of the prion protein. Biomed. Pharmacother. 53:1999;39-46.
32. Bounhar Y., Zhang Y., Goodyer C.G., LeBlanc A. Prion protein protects human neurons against Bax-mediated apoptosis. J. Biol. Chem. 276:2001;39145-39149.
33. Milhiet P.E., Giocondi M.C., Baghdadi O., Ronzon F., Roux B., Le Grimellec C. Spontaneous insertion and partitioning of alkaline phosphatase into model lipid rafts. EMBO Rep. 3:2002;485-490.
34. Saslowsky D.E., Lawrence J., Ren X., Brown D.A., Henderson R.M., Edwardson J.M. Placental alkaline phosphatase is efficiently targeted to rafts in supported lipid bilayers. J. Biol. Chem. 277:2002;26966-26970.
35. Delecluse H.J., Hilsendegen T., Pich D., Zeidler R., Hammerschmidt W. Propagation and recovery of intact, infectious Epstein-Barr virus from prokaryotic to human cells. Proc. Natl Acad. Sci. USA. 95:1998;8245-8250.
36. Gruffat H., Batisse J., Pich D., Neuhierl B., Manet E., Hammerschmidt W., Sergeant A. Epstein-Barr virus mRNA export factor EB2 is essential for production of infectious virus. J. Virol. 76:2002;9635-9644.
37. Goh W.C., Rogel M.E., Kinsey C.M., Michael S.F., Fultz P.N., Nowak M.A., et al. HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nature Med. 4:1998;65-71.
38. Hrimech M., Yao X.J., Branton P.E., Cohen E.A. Human immunodeficiency virus type 1 Vpr-mediated G(2) cell cycle arrest: Vpr interferes with cell cycle signaling cascades by interacting with the B subunit of serine/threonine protein phosphatase 2A. EMBO J. 19:2000;3956-3967.
39. Purcell D.F., Martin M.A. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J. Virol. 67:1993;6365-6378.
40. Chazal N., Gerlier D. Virus entry, assembly, budding, and membrane rafts. Microbiol. Mol. Biol. Rev. 67:2003;226-237.
41. Llano M., Kelly T., Vanegas M., Peretz M., Peterson T.E., Simari R.D., Poeschla E.M. Blockade of human immunodeficiency virus type 1 expression by caveolin- 1. J. Virol. 76:2002;9152-9164.
42. Weiss S., Proske D., Neumann M., Groschup M.H., Kretzschmar H.A., Famulok M., Winnacker E.L. RNA aptamers specifically interact with the prion protein PrP. J. Virol. 71:1997;8790-8797.
43. Brasey A., Lopez-Lastra M., Ohlmann T., Beerens N., Berkhout B., Darlix J.L., Sonenberg N. The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J. Virol. 77:2003;3939-3949.
44. Freed E.O. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology. 251:1998;1-15.
45. Ritter G.D. Jr, Yamshchikov G., Cohen S.J., Mulligan M.J. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J. Virol. 70:1996;2669-2673.
46. Basyuk E., Galli T., Mougel M., Blanchard J.M., Sitbon M., Bertrand E. Retroviral genomic RNAs are transported to the plasma membrane by endosomal vesicles. Dev. Cell. 5:2003;161-174.
47. Pelchen-Matthews A., Kramer B., Marsh M. Infectious HIV-1 assembles in late endosomes in primary macrophages. J. Cell Biol. 162:2003;443-455.
48. Sunyach C., Jen A., Deng J., Fitzgerald K.T., Frobert Y., Grassi J., et al. The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein. EMBO J. 22:2003;3591-3601.
49. Peters P.J., Mironov A., Peretz D., Van Donselaar E., Leclerc E., Erpel S., et al. Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J. Cell Biol. 162:2003;703-717.
50. Mahfoud R., Garmy N., Maresca M., Yahi N., Puigserver A., Fantini J. Identification of a common sphingolipid-binding domain in alzheimer, prion, and HIV-1 proteins. J. Biol. Chem. 277:2002;11292-11296.
51. Saez-Cirion A., Nieva J.L., Gallaher W.R. The hydrophobic internal region of bovine prion protein shares structural and functional properties with HIV type 1 fusion peptide. AIDS Res. Hum. Retroviruses. 19:2003;969-978.
52. Zou W.Q., Zheng J., Gray D.M., Gambetti P., Chen S.G. Antibody to DNA detects scrapie but not normal prion protein. Proc. Natl Acad. Sci. USA. 101:2004;1380-1385.
53. Thackray A.M., Bujdoso R. PrP(c) expression influences the establishment of herpes simplex virus type 1 latency. J. Virol. 76:2002;2498-2509.
54. Carp R.I., Meeker H.C., Caruso V., Sersen E. Scrapie strain-specific interactions with endogenous murine leukaemia virus. J. Gen. Virol. 80:1999;5-10.
55. Manuelidis L. Transmissible encephalopathies: speculations and realities. Virol. Immunol. 16:2003;123-139.
56. Murdoch G.H., Sklaviadis T., Manuelidis E.E., Manuelidis L. Potential retroviral RNAs in Creutzfeldt-Jakob disease. J. Virol. 64:1990;1477-1486.
57. Akowitz A., Manuelidis E.E., Manuelidis L. Protected endogenous retroviral sequences copurify with infectivity in experimental Creutzfeldt-Jakob disease. Arch. Virol. 130:1993;301-316.
58. Akowitz A., Sklaviadis T., Manuelidis L. Endogenous viral complexes with long RNA cosediment with the agent of Creutzfeldt-Jakob disease. Nucl. Acids Res. 22:1994;1101-1107.
59. Gervaix A., West D., Leoni L.M., Richman D.D., Wong-Staal F., Corbeil J. A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc. Natl Acad. Sci. USA. 94:1997;4653-4658.
60. Nishida N., Harris D.A., Vilette D., Laude H., Frobert Y., Grassi J., Casanova D., Milhavet O., Lehmann S. Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein. J. Virol. 74:2000;320-325.
61. Pickl W.F., Pimentel-Muinos F.X., Seed B. Lipid rafts and pseudotyping. J. Virol. 75:2001;7175-7183.
62. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:1986;284-291.
63. Jaegly A., Mouthon F., Peyrin J.M., Camugli B., Deslys J.P., Dormont D. Search for a nuclear localization signal in the prion protein. Mol. Cell Neurosci. 11:1998;127-133.
64. Hughes S.H., Greenhouse J.J., Petropoulos C.J., Sutrave P. Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors. J. Virol. 61:1987;3004-3012.
65. van den Heuvel S., Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science. 262:1993;2050-2054.
66. Cimarelli A., Luban J. Human immunodeficiency virus type 1 virion density is not determined by nucleocapsid basic residues. J. Virol. 74:2000;6734-6740.
67. Ilangumaran S., Arni S., Chicheportiche Y., Briol A., Hoessli D.C. Evaluation by dot-immunoassay of the differential distribution of cell surface and intracellular proteins in glycosylphosphatidylinositol-rich plasma membrane domains. Anal. Biochem. 235:1996;49-56.
68. Nguyen D.H., Hildreth J.E. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J. Virol. 74:2000;3264-3272.
69. Berthoux L., Pechoux C., Darlix J.L. Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication. J. Virol. 73:1999;10000-10009.